AGILIS¿ INTRODUCER, UNKNOWN
Report
- Report Number
- 2182269-2019-00067
- Event Type
- Injury
- Date Received
- May 22, 2019
- Report Date
- May 22, 2019
- Manufacturer
- ST. JUDE MEDICAL, INC.
- Product Code
- DYB
- PMA / PMN Number
- K061363
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- PHYSICIAN
Narratives
THE RESULTS OF THE INVESTIGATION ARE INCONCLUSIVE SINCE THE DEVICE WAS NOT RETURNED FOR ANALYSIS. BASED ON THE INFORMATION RECEIVED, THE CAUSE OF THE REPORTED FEMORAL ARTERIOVENOUS FISTULA COULD NOT BE CONCLUSIVELY DETERMINED.
THE FOLLOWING WAS PUBLISHED IN THE JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY IN AN ARTICLE TITLED ¿CATHETER ABLATION OF ATRIAL FIBRILLATION WITH NON-FLUOROSCOPIC CATHETER VISUALIZATION¿A PROSPECTIVE RANDOMIZED COMPARISON" BY SASCHA ROLF, KATHARINA SCHOENE, ET AL., 18 SEPTEMBER 2018. THIS IS THE FIRST STUDY OF PROSPECTIVE RANDOMIZED COMPARISON OF FLUOROSCOPY NEEDS, PROCEDURE TIMES, AND COMPLICATIONS IN ATRIAL FIBRILLATION (AF) CATHETER ABLATION WITH OR WITHOUT ADDITIONAL USE OF NON-FLUOROSCOPIC CATHETER VISUALIZATION (NFCV). BETWEEN MARCH 2013 AND SEPTEMBER 2014, A TOTAL OF 80 PATIENTS WERE PROSPECTIVELY RANDOMIZED IN A 1:1 FASHION TO EITHER AF CATHETER ABLATION WITH ELECTRO-ANATOMICAL MAPPING SYSTEM ALONE (ENSITE NAVX¿) OR WITH THE ADDITION OF THE NFCV TECHNOLOGY. ALL PROCEDURES WERE PERFORMED IN THE SAME LAB USING THE SAME ABLATION CATHETER TIP TECHNOLOGY AND THE SAME MAPPING AND ABLATION STRATEGIES. ISOLATION OF ALL FOUR PULMONARY VEINS BY CIRCUMFERENTIAL ABLATION AS CONFIRMED BY A CIRCULAR MAPPING CATHETER WAS ACHIEVED IN ALL PATIENTS. ONE PATIENT IN THE FIRST COHORT EXPERIENCED A FEMORAL ARTERIOVENOUS FISTULA, WHICH DID NOT REQUIRE SURGICAL TREATMENT. NO OTHER COMPLICATIONS OCCURRED. (DOI: 10.1007/S10840-018-0446-8).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 424525 | AGILIS¿ INTRODUCER, UNKNOWN | INTRODUCER | DYB | ST. JUDE MEDICAL, INC. |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Other |